Investigator Perspectives

Investigator Perspectives

Targeted Oncology presents Investigator Perspectives, a video series featuring key opinion leaders discussing how to approach and manage patients with different tumor types.

Treating Radioactive Iodine-Refractory Differentiated Thyroid Cancer (RAI-R-DTC) with Lenvatinib

November 16th 2022

Lori Wirth, MD, reviews real-world and clinical trial data on treatment of advanced radioactive iodine-refractory differentiated thyroid cancer (RAI-R-DTC) with lenvatinib, and her personal experience with lenvatinib in clinical practice.

Immune Checkpoint Inhibitor Metastatic NSCLC: Combination Strategies

November 15th 2022

Edward B. Garon, MD, MS, provides his expert perspective on immune checkpoint inhibition in metastatic non-small cell lung cancer (mNSCLC) and evaluates the currently available immunotherapy combinations.

Potential Role of Elacestrant for the Treatment of Metastatic ER+/HER2- Breast Cancer

October 31st 2022

Dr Aditya Bardia reviews the potential role of elacestrant for the treatment of metastatic ER+/HER2- breast cancer, starting with an overview of the current landscape and focusing specifically on key efficacy data from the EMERALD Trial.

The Evolving Treatment Landscape for Myelofibrosis

August 18th 2022

Naveen Pemmaraju, MD, explains the types of myeloproliferative neoplasms, the currently available treatment options, and how treatment approaches have changed historically.

The Current Field of Graft Versus Host Disease

June 30th 2022

Robert Zeiser, MD, discusses the landscape of graft versus host disease and reviews data related to the current treatment options.

Use of Venetoclax in Newly Diagnosed Acute Myeloid Leukemia (AML)

June 22nd 2022

Courtney DiNardo, MD, discusses the use of venetoclax in newly-diagnosed acute myeloid leukemia, with a review of data from the VIALE-A clinical trial.

The Phase 2 REFINE Trial: Ruxolitinib Plus Navitoclax for Myelofibrosis

April 19th 2022

Naveen Pemmaraju, MD, provides his expert perspective on currently available treatment options in myelofibrosis and data from the REFINE trial on the experimental therapy of ruxolitinib plus navitoclax.

Metastatic Castration-Resistant Prostate Cancer: Updates to VISION Trial Data

April 14th 2022

Scott Tagawa, MD, MS, FACP, comments on treatment and management strategies in metastatic castration-resistant prostate cancer (CRPC), and reviews recent data on the VISION trial of Lu 177 vipivotide tetraxetan.

The Phase 3 CLEAR Trial: Lenvatinib Plus Pembrolizumab or Everolimus for Advanced RCC

March 18th 2022

Recommendations for treating advanced renal cell carcinoma with the combination of lenvatinib plus pembrolizumab or lenvatinib plus everolimus, as suggested by Moshe Ornstein, MD.

Endometrial Carcinoma Treatment Advances

January 14th 2022

Expert gynecologic oncologist Brian Slomovitz, MD, MS, FACOG, shares insight on novel therapeutic approaches to the management of endometrial cancer.